The first drug profiled, etomidate, has been improved by researchers at Massachusetts General Hospital. The researchers were able to improve the drug so that it does not interfere with the immune system, a current side effect of the agent.
The second, remimazolam, is a new benzodiazepine-type sedative drug with predictable effects and a comparatively rapid recovery time.
More Articles on Anesthesia:
FDA Approves Mylan’s Generic Anesthesia Drug Etomidate
Improving Perioperative Efficiency, Quality Requires Nursing-Anesthesia Partnership
